Request Demo
Fierce Pharma Asia—Astellas' eye drug nod; Singapore's biotech dream; AstraZeneca's CanSino mRNA deal
VaccineDrug ApprovalImmunotherapymRNAAcquisition
Astellas' geographic atrophy approval, Singapore's 20 years of work on advancing biotech, and AstraZeneca and CanSino's mRNA deal made our news this week.
Astellas has won FDA approval for a geographic atrophy therapy that the company obtained from AstraZenecation CanSinoic Bio. A Fierce Biotech report examined Singapore's biotech landscape 20 years into a nationwide initiative to become a biotech hub. AstraZeneca signed an mRNA vaccine manufacturing deal with China's CanSino Biologics. And more.
Astellaslas wins FDA approval of eyegeographic atrophyvay and may have edge in market battle with ApellisIveric BioAstraZenecaCanSino Biologics
AstAstellas5.9 biFDAon acquisitioeye disease Bio hIzervaye fruit. The FDA has approved Iveric’s geApellisc atrophy therapy Izervay. The nod came less than six months after Apellis’ Syfovre became the first FDA-approved therapy for the eye disease. Syfovre’s first-to-market edge was recently diminished by reports of severe side effects.
Astellasars in, Singapore still searchIveric Bio biotech success storyFDAIvericgeographic atrophyIzervayApellisSyfovreFDAeye diseaseSyfovre
In a new report, Fierce Biotech examined Singapore’s biotech ambition 20 years after a government-led push to become a biotech hub. Temasek-backed Tessa Therapeutics’ sudden dissolution inevitably weakened investors’ confidence in Singapore’s biotech industry, which also faces a talent shortage. But observers and stakeholders believe Singapore may still have a big biotech success story.
3. AstraZeneca pursues mRNA, signs vaccine manufacturing deal with China's CanSinoTemasekTessa Therapeutics
AstAstraZenecagned an mRNA manufacturing deal with China’s CanSino BiologicCanSinoChinese company will help make certain vaccines by AZ during R&D. The deal comes a year after AZ axed an mRNA strategic partnership with Moderna in cardiovascular and oncology.
AstraZenecaSankyo tipped to dominate antibody-drug conjugatCanSino Biologics2029Moderna
WitDaiichi Sankyopartnered Enhertu leading the way, Daiichi Sankyo will be the top antibody-drug conjugate player through 2029, GlobalData predicted. Sales from Daiichi’s ADCs will reach $10 billion by then, while Seagen and Roche will follow as distant second and third, respectively. In a recent update, Daiichi itself expects its oncology revenue could reach over $6.3 billion by its 2025 fiscal year.
5. PoAstraZeneca $50M stakeEnhertuellas, extending cDaiichi Sankyogene therapy programs reviewedDaiichiSeagenRocheDaiichi
SK Biosciencewhere an AsiNovavaxharma company bought stakes in a U.S. firm, SK Bioscience injected $85 million into floundering vaccine maker Novavax for a 7% holding, and Astellas put up $50 million in exchange for an 8.8% stake in Poseida Therapeutics and the right of first negotiation for P-MUC1C-ALLO1, a CAR-T cell therapy under development for solid tumors.
7. Takeda, Denali drop Alzheimer's asset after phase 1 peak reveals 'narrow SK Bioscienceindow'NovavaxAstellasPoseida TherapeuticsP-MUC1C-ALLO1CAR-T cellsolid tumors
Takeda and Denali Therapeutics have decided to stop developing their Alzheimer’s disease candidate TAK-920. Takeda signed up to co-develop the antibody transport vehicle back in 2021. But the drug soon hit an FDA clinical hold, and new phase 1 data suggested the drug was too toxic at a high dose. Takeda and Denali are now looking at back-up molecules.
Takedaeda sDenali Therapeuticsettle Medicaid fraud claims in TexasAlzheimer’s diseaseTAK-920TakedaFDATakedaDenali
TakTakedas agreed to pay $42 million in Texas to resolve a whistleblower case that accused the company’s Shire unit of paying clinical nurse educators to refer and recommend ADHD drug Vyvanse to doctors in 2014 and 2015. Takeda denied the claims but said the deal is “in patients’ best interest.”
9. Astellas plots new Cambridge facility for R&D, business development (Release)
10.Astellash expands DualityBio pact to include 3rd ADC (Release)
11. BioNTechBio snaps up Glympse Bio for protein-based diagnostics
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.